Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11737724 | 0.82 | PKM (0.30) | — | |
| SCHEMBL7512602 | 0.77 | — | — | |
| SCHEMBL28064595 | 0.75 | PTGS1 (0.31) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL8629829 | 0.72 | — | — | |
| SCHEMBL5736042 | 0.72 | LMNA (0.39) | PTGS2TSHRLMNA | |
| SCHEMBL9147377 | 0.72 | AKR1B1 (0.32) | — | |
| SCHEMBL1176805 | 0.71 | — | — | |
| SCHEMBL183024 | 0.69 | ALDH1A1 (0.31) | — | |
| SCHEMBL11724427 | 0.67 | ALOX15 (0.30) | — | |
| SCHEMBL3971345 | 0.67 | HPGD (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108299353-A | A kind of preparation method of 5- formic acid ester group furan compound | 中国科学院宁波材料技术与工程研究所 | 2018-07-20 | — | — | CN | claimed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| EP-1307204-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-06-02 | — | — | EP | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| CN-1444481-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| EP-1307204-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | claimed |
| CN-113715193-B | Furanoic acid polymer preforms, containers, and processing | 可口可乐公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-108299353-A | A kind of preparation method of 5- formic acid ester group furan compound | 中国科学院宁波材料技术与工程研究所 | 2018-07-20 | — | — | CN | disclosed |
| CN-108299351-A | Preparation method of 2, 5-disubstituted furan compound | 中国科学院宁波材料技术与工程研究所 | 2018-07-20 | — | — | CN | disclosed |
| EP-3143068-B1 | THERMOPLASTIC AROMATIC POLYESTERS COMPRISING TETRAHYDROFURAN-DIMETHANOL AND FURANDICARBOXYLIC ACID MOTIFS | ROQUETTE FRERES (FR) | 2018-05-02 | — | — | EP | disclosed |
| EP-3143068-A1 | THERMOPLASTIC AROMATIC POLYESTERS COMPRISING TETRAHYDROFURAN-DIMETHANOL AND FURANDICARBOXYLIC ACID MOTIFS | Roquette Frères (FR) | 2017-03-22 | — | — | EP | disclosed |
| EP-0482433-B1 | Wood preserving agents containing polymeric nitrogen compounds and metal fixing acids | WOLMAN GMBH DR (DE) | 1995-01-25 | — | — | EP | disclosed |
| US-5186947-A | Copper and zinc compounds, a metal fixing acid, and a polyethylenimine washout reducing compound | DR. WOLMAN GMBH (DE) | 1993-02-16 | — | — | US | disclosed |
| EP-0482433-A1 | Wood preserving agents containing polymeric nitrogen compounds and metal fixing acids | Dr. Wolman GmbH (DE) | 1992-04-29 | — | — | EP | disclosed |
| CN-1060469-A | Process for preparing cephalosporin derivatives | BEECHAM GROUP PLC (GB) | 1992-04-22 | — | — | CN | disclosed |
| US-4013684-A | PREPARATION OF 2,5-DIMETHYLFURAN-3-CARBOXYLIC AMIDES | BADISCHE ANILIN- & SODA-FABRIK AKTIENGESELLSCHAFT (DT) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | PTGS1 637/4885PTGS2 1315/4885CYP1A2 2704/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | PTGS1 424/4885PTGS2 1096/4885CYP1A2 3227/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | PTGS1 637/4885PTGS2 1315/4885CYP1A2 2704/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | PTGS1 637/4885PTGS2 1315/4885CYP1A2 2704/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | PTGS1 637/4885PTGS2 1315/4885CYP1A2 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.